



## Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

November 4, 2025

NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- [Acumen Pharmaceuticals, Inc.](#) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at 4:40 p.m. ET.

The live webcasts may be accessed under the Investors tab on [www.acumenpharm.com](http://www.acumenpharm.com) and will be archived for 90 days.

### About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A $\beta$ Os) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on A $\beta$ Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A $\beta$ Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD.

Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE<sup>®</sup> drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD<sup>™</sup>) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit [www.acumenpharm.com](http://www.acumenpharm.com).

### Investors:

Alex Braun  
[abraun@acumenpharm.com](mailto:abraun@acumenpharm.com)

### Media:

[AcumenPR@westwicke.com](mailto:AcumenPR@westwicke.com)